Highly focused stereotactic body radiation therapy can eliminate tumors better than conventional radiotherapy and may improve survival for inoperable non-small cell lung cancer, according to a Radiation Therapy Oncology Group study.
Highly focused stereotactic body radiation therapy can eliminate tumors better than conventional radiotherapy and may improve survival for inoperable non-small cell lung cancer, according to a Radiation Therapy Oncology Group study.
The most exciting aspect of the prospective study was the high rate of primary tumor control-97.6%-at three years, according to Dr. Robert Timmerman, a professor at the University of Texas Southwestern Medical Center in Dallas and principal investigator of the study.
Stereotactic body radiation therapy as delivered in the trial more than doubled the rate of primary tumor control provided by conventional radiotherapy, he said. This suggests the technique could provide a significant step forward in the battle against inoperable non-small cell lung cancer.
The phase II study included 59 patients with biopsy-proven peripheral non-small cell tumors measuring less than 5 cm in diameter with conditions disallowing surgical treatment.
This was the first North American multicenter cooperative group study to test stereotactic body radiation therapy in treating these types of patients. It was published in the March 17 Journal of the American Medical Association.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.